<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501616</url>
  </required_header>
  <id_info>
    <org_study_id>BRMH 26-2014-148</org_study_id>
    <nct_id>NCT02501616</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozine on Systemic and Renal Endothelial Function</brief_title>
  <official_title>Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      This is a phase 4, single center, randomized, open-labeled, cross-over design study. The
      primary objective of the study is to compare effect of dapagliflozine and metformin on
      endothelial function.

      Subjects are randomized to initial metformin or initial dapagliflozin group and maintained
      initial treatment for 8 weeks. During that period, dose of dapagliflozin is maintained
      10mg/day and metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8
      weeks' cross-over is followed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive hyperemic index to measure endothelial function</measure>
    <time_frame>8 weeks</time_frame>
    <description>endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N-acetyl-β-D-glucosaminidase as a measure of renal tubular injury</measure>
    <time_frame>8 week</time_frame>
    <description>renal tubular injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine albumin excretion ratio</measure>
    <time_frame>8 week</time_frame>
    <description>Urine albumin excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine β2 microglobulin</measure>
    <time_frame>8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Endothelial Function</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin first 8 wks --&gt; Dapagliflozin 8wks.
Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin first 8 wks --&gt; Metformin 8wks.
Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin first</arm_group_label>
    <arm_group_label>Dapagliflozin first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>Metformin first</arm_group_label>
    <arm_group_label>Dapagliflozin first</arm_group_label>
    <other_name>Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Present with type 2 diabetes based on the disease diagnostic criteria as described by
             the World Health Organization (WHO)

          2. Treated with diet and exercise alone for recent 3 months

          3. Aged 20-80 years

          4. HbA1c 7~9%

          5. This inclusion criterion applies to females of childbearing potential (not surgically
             sterilized and between menarche and 1-year postmenopause) only.

               -  Are not breastfeeding.

               -  Test negative for pregnancy at the time of screening based on a blood serum
                  pregnancy test.

               -  Intend not to become pregnant during the study.

        Exclusion Criteria:

          1. Previous history of IHD or brain infarct

          2. Having typical anginal pain or atypical chest pain with dyspnea

          3. Modification of Diet in Renal Disease (MDRD) estimated GFR≥60 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Kyong Moon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boramae medical center, 20 Boramae-ro 5-gil,Dongjak-Gu,Seoul 156-707, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Kyong Moon, MD PhD</last_name>
    <phone>+82-2-870-2226</phone>
    <email>mkmoon@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Kyung Koo, MD PhD</last_name>
    <phone>+82-2-870-2225</phone>
    <email>bokyungkoomd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boramae medical center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bokyung Koo</last_name>
      <email>bokyungkoomd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Min Kyong Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Min Kyong Moon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>SGLT2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

